Switching from Ozempic to Wegovy for weight loss: what you need to decide

Same molecule, different licence, and why that is not a small detail

Ozempic and Wegovy are both semaglutide, a GLP-1 receptor agonist that slows gastric emptying, reduces appetite and influences blood-sugar regulation. The difference sits in what each product is authorised to do. Ozempic is licensed in the UK for type 2 diabetes management. Wegovy, at the higher 2.4 mg weekly maintenance dose, is licensed for chronic weight management in adults without a diabetes diagnosis, and for those with type 2 diabetes too, subject to clinical criteria. The MHRA's guidance is clear: semaglutide in its Wegovy formulation is the one assessed for weight loss.

If you have been using Ozempic off-label for weight loss, you may already have experienced real benefit. The question of whether to switch to Wegovy is partly about moving onto the correct licensed product for the purpose you are using it for, and partly about dose. Ozempic tops out at 1 mg weekly; Wegovy's maintenance dose goes up to 2.4 mg, with a newer 7.2 mg single-dose pen approved by the MHRA in April 2026. For many people, that higher ceiling is the practical reason to make the change, and our page on whether you can switch from Ozempic to Wegovy covers the key considerations in full. You can read a fuller breakdown on our Wegovy vs Ozempic for weight loss page.

What the evidence says about the doses you would be moving between

The trial data is worth knowing before you decide. The STEP 1 trial, published in the New England Journal of Medicine, followed adults using semaglutide 2.4 mg weekly for 68 weeks and recorded an average weight reduction of around 15%. If you want to understand how the two products compare as weight-loss options, our page on Ozempic vs semaglutide for weight loss sets out what the evidence shows and where the distinctions lie. Ozempic studies, designed for glycaemic control rather than weight outcomes, used lower doses and different endpoints, comparing them directly is not straightforward.

The table below sets out the key factual differences between the two products as they stand in the UK today.

The higher licensed dose ceiling is the main clinical argument for switching, provided your prescriber agrees you are a suitable candidate. Our Ozempic versus Wegovy for weight loss page explores the evidence comparison in more depth.

How the switch actually works in practice

If you are currently on Ozempic and want to move to Wegovy, the transition is not automatic. A prescriber needs to know your current dose, how long you have been on treatment, any side effects you have had, and your current weight. Someone who has been stable on Ozempic 0.5 mg for six months is in a different clinical position to someone who started last month and is still managing nausea.

In general terms, switching between semaglutide formulations does not mean starting from scratch at 0.25 mg, but the right starting point for Wegovy depends on individual factors and is always the prescriber's call, guided by the product's Patient Information Leaflet. What you will not get from our prescribers is a blanket "yes, carry on at the same dose" without that review. That is the point of having a real clinician look at your notes. If you want more detail on the practical steps involved, the switching from Ozempic to Wegovy page walks through the process. Our clinical team oversees every prescription personally.

Wegovy is available on the NHS through specialist weight management services under NICE guidance TA875, though waiting lists are commonly long. Through a regulated private pharmacy such as ours, eligible patients can access it without a referral, subject to the same clinical standards. Specific dose availability is confirmed at the point of consultation, a detail worth asking about during your review.

What is licensed for weight loss in the UK, and what comes next

Because Ozempic is not a weight-loss medicine in UK law, our prescribers do not issue it for that purpose. The two medicines we do prescribe for weight management are Wegovy (semaglutide) and Mounjaro (tirzepatide). Mounjaro is a dual GIP and GLP-1 receptor agonist (the only medicine of that type licensed in the UK) and produced greater average weight reduction than semaglutide 2.4 mg in the SURMOUNT-5 head-to-head trial published in 2025. Some patients considering a switch from Ozempic to Wegovy find it worth discussing both options at the same time rather than making two separate changes. You can compare them on our weight-loss treatments overview page.

If cost is part of your thinking, our Wegovy cost page explains what the private price includes and what context to put around it. The short version: the figure that matters is not the lowest number you can find online, but whether the supply chain, the clinical oversight and the pharmacy dispensing it are verifiable. You can check any online pharmacy on the GPhC register, ours is registered under premises number 9012878. Which of the licensed medicines suits your situation is a clinical decision our prescribers make with you, not something this page can settle for you.